ID
15433
Beschrijving
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01) https://clinicaltrials.gov/ct2/show/NCT02419378 Principal Investigator Prof. Dr. Dr. Sven Meuth, University Hospital Muenster, Germany Part: Repitition of Assessments Please complete the following pages only if Baseline Assessments had to be repeated prior to initiation of Lemtrada® (relapse after first examination, see Study Protocol 8.1.1.2)
Link
https://clinicaltrials.gov/ct2/show/NCT02419378
Trefwoorden
Versies (1)
- 31-05-16 31-05-16 -
Geüploaded op
31 mei 2016
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Baseline: Repitition of Assessments: EDSS Multiple Sclerosis ALAIN01 NCT02419378
Baseline: Repitition of Assessments EDSS Multiple Sclerosis ALAIN01 NCT02419378
Similar models
Baseline: Repitition of Assessments EDSS Multiple Sclerosis ALAIN01 NCT02419378
C0011008 (UMLS CUI [1,2])
C1321512 (UMLS CUI [1,2])
C0006121 (UMLS CUI [1,2])
C0228060 (UMLS CUI [1,2])
C0007765 (UMLS CUI [1,2])
C0682648 (UMLS CUI [1,2])
C0006104 (UMLS CUI [1,2])
C0080331 (UMLS CUI [1,2])
C0007765 (UMLS CUI [1,2])
Geen commentaren